Cover Image
市場調查報告書

補體C5:開發中產品分析

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363122
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
補體C5:開發中產品分析 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 110 Pages
簡介

本報告提供補體C5藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

補體C5概要

治療藥的開發

補體C5:開發中的產品 - 各開發階段

補體C5:開發中的產品 - 治療範圍別

補體C5:開發中的產品 - 各適應症

補體C5:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

補體C5:企業開發中的產品

補體C5:大學/機關開發中的產品

補體C5:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

補體C5治療藥的開發企業

  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Epirus Biopharmaceuticals, Inc.
  • InflaRx GmbH
  • Novartis AG
  • Noxxon Pharma AG
  • Ophthotech Corp.
  • Ra Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB

補體C5:藥物簡介

補體C5:暫停中的計劃

補體C5:中止開發的產品

補體C5:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0591TDB

Summary

Global Markets Direct's, 'Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016', provides in depth analysis on Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted pipeline therapeutics.

The report provides comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
  • The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Overview
  • Therapeutics Development
    • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Stage of Development
    • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Therapy Area
    • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Indication
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Companies
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Universities/Institutes
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
    • Akari Therapeutics, Plc
    • Alexion Pharmaceuticals Inc
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc.
    • Epirus Biopharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • InflaRx GmbH
    • Novartis AG
    • Noxxon Pharma AG
    • Ophthotech Corp.
    • Ra Pharmaceuticals, Inc.
    • Swedish Orphan Biovitrum AB
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
    • AcPepA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-CC5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALXN-1007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALXN-1210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALXN-5500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avacincaptad pegol sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bikaciomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BikajuMab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Coversin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Coversin LA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IFX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IFX-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mubodina - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NM-9405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Inhibit Complement C5 for Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101295 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101348 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101495 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-7112689 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOBI-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tesidolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Projects
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Featured News & Press Releases
    • Sep 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
    • Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease
    • Jul 13, 2016: Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria
    • Jul 12, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria
    • Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress
    • Jul 06, 2016: Federal Court Dismisses Challenge to Constitutionality of Federal Government's Drug Price Watchdog
    • Jul 06, 2016: Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin
    • Jun 11, 2016: Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study
    • Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association
    • Jun 10, 2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
    • Jun 10, 2016: Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association
    • Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery
    • Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
    • Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
    • Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Akari Therapeutics, Plc, H2 2016
  • Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pipeline by InflaRx GmbH, H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Noxxon Pharma AG, H2 2016
  • Pipeline by Ophthotech Corp., H2 2016
  • Pipeline by Ra Pharmaceuticals, Inc., H2 2016
  • Pipeline by Swedish Orphan Biovitrum AB, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top